Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34039
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSullivan, Jennifer A-
dc.contributor.authorSpillmann, Rebecca C-
dc.contributor.authorSchoch, Kelly-
dc.contributor.authorWalley, Nicole-
dc.contributor.authorAlkelai, Anna-
dc.contributor.authorStong, Nicholas-
dc.contributor.authorShea, Patrick R-
dc.contributor.authorPetrovski, Slavè-
dc.contributor.authorJobanputra, Vaidehi-
dc.contributor.authorMcConkie-Rosell, Allyn-
dc.contributor.authorShashi, Vandana-
dc.date2023-
dc.date.accessioned2023-10-25T06:18:55Z-
dc.date.available2023-10-25T06:18:55Z-
dc.date.issued2024-01-
dc.identifier.citationClinical Genetics 2024-01; 105(1)en_US
dc.identifier.issn1399-0004-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/34039-
dc.description.abstractGenomic medicine has been transformed by next-generation sequencing (NGS), inclusive of exome sequencing (ES) and genome sequencing (GS). Currently, ES is offered widely in clinical settings, with a less prevalent alternative model consisting of hybrid programs that incorporate research ES along with clinical patient workflows. We were among the earliest to implement a hybrid ES clinic, have provided diagnoses to 45% of probands, and have identified several novel candidate genes. Our program is enabled by a cost-effective investment by the health system and is unique in encompassing all the processes that have been variably included in other hybrid/clinical programs. These include careful patient selection, utilization of a phenotype-agnostic bioinformatics pipeline followed by manual curation of variants and phenotype integration by clinicians, close collaborations between the clinicians and the bioinformatician, pursuit of interesting variants, communication of results to patients in categories that are predicated upon the certainty of a diagnosis, and tracking changes in results over time and the underlying mechanisms for such changes. Due to its effectiveness, scalability to GS and its resource efficiency, specific elements of our paradigm can be incorporated into existing clinical settings, or the entire hybrid model can be implemented within health systems that have genomic medicine programs, to provide NGS in a scientifically rigorous, yet pragmatic setting.en_US
dc.language.isoeng-
dc.subjectMendelian disordersen_US
dc.subjectexome sequencingen_US
dc.subjectgenome sequencingen_US
dc.subjectnext-generation sequencingen_US
dc.subjectrare disordersen_US
dc.subjectultra-rare disordersen_US
dc.subjectundiagnosed diseasesen_US
dc.titleThe best of both worlds: Blending cutting-edge research with clinical processes for a productive exome clinic.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleClinical Geneticsen_US
dc.identifier.affiliationDepartment of Pediatrics, Division of Medical Genetics, Duke University, Durham, North Carolina, USA.en_US
dc.identifier.affiliationInstitute for Genomic Medicine, Columbia University Medical Center, New York, New York, USA.;Regeneron Genetics Center, Regeneron Pharmaceuticals, Tarrytown, New York, USA.en_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.identifier.affiliationDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.en_US
dc.identifier.doi10.1111/cge.14437en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0003-3742-7799en_US
dc.identifier.pubmedid37853563-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

44
checked on Dec 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.